Welcome to our dedicated page for Trinity Biotech Plc news (Ticker: TRIB), a resource for investors and traders seeking the latest updates and insights on Trinity Biotech Plc stock.
Trinity Biotech plc (NASDAQ: TRIB) is a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors. The TRIB news feed on Stock Titan aggregates company press releases and related coverage so readers can follow developments across its infectious disease, diabetes, oncology and maternal health portfolios.
News items for Trinity Biotech commonly highlight regulatory milestones and product launches. Recent announcements include large orders for its TrinScreen HIV rapid screening test, WHO and in-country regulatory approvals enabling offshored and outsourced manufacturing of TrinScreen HIV and Uni-Gold HIV, and expanded rollout of a high-capacity HbA1c column system for the FDA-cleared Premier Hb9210 analyzer. These updates provide insight into how the company is executing its transformation plan and adjusting its manufacturing footprint.
Investors and observers can also use the TRIB news page to track progress in newer areas such as continuous glucose monitoring, where the company has reported breakthrough clinical trial results for a redesigned CGM sensor and references its CGM+ solution, as well as oncology and maternal health initiatives, including development of the EpiCapture prostate cancer test and the PreClara Ratio preeclampsia biomarker service. Capital structure and governance developments, such as credit agreement amendments with Perceptive Advisors, Nasdaq listing compliance updates, and annual general meeting outcomes, are also disclosed through news and associated SEC filings.
By reviewing the Trinity Biotech news stream, users can see how product approvals, manufacturing changes, financing arrangements and clinical data releases intersect with the company’s stated strategy in diagnostics and diabetes management. This page can be revisited to follow new regulatory clearances, commercial orders, pipeline updates and corporate actions as they are reported by the company.
Trinity Biotech plc (Nasdaq: TRIB) has announced increased orders for its TrinScreen HIV product, leading to an upward revision of its 2024 sales guidance. The company now expects TrinScreen HIV sales to reach approximately $10 million in 2024, up from the previous estimate of $8 million. This increase is attributed to strong demand and successful scaling of production capacity.
Additionally, Trinity Biotech has increased manufacturing capacity for FlexTrans™, its FDA 510(k) cleared viral transport medium, in anticipation of potential increased demand due to the WHO's declaration of Mpox as a Public Health Emergency of International Concern. The company aims to contribute to diagnostic testing for this global health threat.
Trinity Biotech plc (Nasdaq: TRIB) has appointed David Ouston as Biosensor Marketing Director to drive growth for its innovative continuous glucose monitoring (CGM) technology. Ouston brings 16 years of experience in the glucose monitoring and diabetes health sectors, including roles at Johnson & Johnson and LifeScan. CEO John Gillard emphasized the importance of this strategic appointment for Trinity's long-term growth, particularly in rapidly expanding diabetes and wellness markets.
Ouston expressed enthusiasm for joining Trinity Biotech, highlighting the company's vision for an accessible and innovative CGM in global markets. He aims to leverage his extensive global leadership experience in promotion and market access strategies for diabetes management devices to help deliver Trinity's disruptive solution worldwide.
Trinity Biotech plc (Nasdaq: TRIB) reported strong Q2 2024 financial results, with total revenues of $15.8 million, up 14% year-over-year and 7.7% quarter-over-quarter. The growth was driven by strong demand in the TrinScreen HIV business. Point-of-Care product revenue reached $4.6 million, growing 119% year-over-year and 53% quarter-over-quarter. The company reiterated its guidance to achieve approximately $20 million of annualized run-rate EBITDASO on annualized run-rate revenues of about $75 million by Q2 2025. Trinity Biotech continues to make progress on its Comprehensive Transformation Plan, including manufacturing consolidation, supply chain optimization, and corporate services centralization. The company is also advancing its next-generation Continuous Glucose Monitoring system development.
Trinity Biotech plc (Nasdaq: TRIB), a commercial stage biotechnology company specializing in diabetes management solutions and human diagnostics, has announced it will release its Q2 2024 financial results on Wednesday, August 14, 2024. The company will host a conference call at 8:30 AM ET on the same day to discuss the results.
Investors and interested parties can access the call through various methods:
- US Toll-Free: 1-877-407-0784
- International: 1-201-689-8560
- Conference ID: 13748426
- Webcast link available
- Call me™ feature: https://callme.viavid.com/viavid/?callme=true&passcode=13743417&h=true&info=company-email&r=true&B=6
Trinity Biotech plc (Nasdaq: TRIB), a biotechnology company specializing in human diagnostics and diabetes management solutions, has secured an extension from Nasdaq to demonstrate compliance with listing requirements. The company had received a deficiency letter on November 21, 2023, due to its market value of publicly held shares (MVPHS) falling below the $15 million threshold for 30 consecutive business days. After meeting with the Nasdaq Hearings Panel on July 16, 2024, Trinity Biotech was granted an extension until October 31, 2024, to meet the MVPHS Requirement and maintain its listing on The Nasdaq Global Select Market.
Trinity Biotech (Nasdaq: TRIB) announces preliminary Q2 2024 revenues expected between $15.5-$16.0 million, showing significant growth from $13.9 million in Q2 2023. The company reiterates its financial guidance of $20 million annualized run-rate EBITDASO on $75 million annualized run-rate revenues by Q2 2025. Trinity also enters a UK distribution agreement with MedScience, effective August 1, 2024, covering clinical chemistry, infectious disease, and autoimmune products. This partnership aims to expand Trinity's presence in the UK market and support growth objectives. The company attributes revenue growth to initiatives like the new HIV screening product, TrinScreen HIV. Full Q2 2024 earnings report is expected mid-August, providing updates on the Comprehensive Transformation Plan and continuous glucose monitor (CGM) program.
Trinity Biotech (Nasdaq: TRIB) announced the appointment of Louise Tallon as its new Chief Financial Officer (CFO), effective August 2024. Tallon, who is currently Head of Group Finance at Inizio and has over 19 years of experience in the life sciences industry, will succeed Des Fitzgerald, the interim CFO since December 2023. CEO John Gillard expressed confidence in Tallon's ability to drive the company’s transformation and growth, particularly in the launch of their next-generation continuous glucose monitor (CGM). The company reiterated its financial guidance, aiming for $20 million in annualized EBITDASO1 on $75 million in annualized revenues by Q2 2025. Additionally, Ms. Tallon will take over the responsibilities of the departing Chief Accounting Officer, Simon Dunne.
Trinity Biotech (Nasdaq: TRIB) has received regulatory approval to begin its European pre-pivotal trial for its next-generation continuous glucose monitoring (CGM) system. The trial aims to optimize device performance ahead of a pivotal trial scheduled for 2025. The pre-pivotal trial, set to start imminently and expected to conclude by the end of July, will evaluate the analytical performance of the CGM technology enhancements made by Trinity Biotech following its acquisition earlier this year. The collected data will be used to refine the device further. John Gillard, President and CEO, emphasized the importance of the CGM solution and AI-driven analytics as long-term growth drivers for the company.
Trinity Biotech (Nasdaq: TRIB), a commercial-stage biotechnology firm specializing in diabetes management solutions and diagnostics, announces its senior management will attend the 84th Scientific Sessions of the American Diabetes Association. The event is scheduled for June 21-24, 2024, in Orlando, Florida. Trinity Biotech aims to advance its continuous glucose monitoring (CGM) biosensor technology and plans to host meetings with key stakeholders and potential partners. Interested parties can contact Biosensors@trinitybiotech.com for more information.
Trinity Biotech (Nasdaq: TRIB) announced the launch of its continuous glucose monitoring (CGM) microsite, https://cgm.trinitybiotech.com. The site aims to provide key stakeholders with insights into the company's vision for its recently acquired CGM biosensor technology and AI-driven health and wellness analytics platform. The CEO, John Gillard, emphasized the focus on usability, affordability, and sustainability to enhance global accessibility for diabetes management. The microsite will also offer updates on the international commercialization efforts and encourage stakeholders to sign up for newsletters and email alerts.